• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

散发性遗传性转甲状腺素蛋白介导的淀粉样变性患者的诊断延迟

Diagnostic delay in patients with sporadic hereditary transthyretin-mediated amyloidosis.

作者信息

Antunes Bernardo, Conceição Isabel, Falcão de Campos Catarina, de Carvalho Mamede

机构信息

Instituto de Fisiologia, Centro de Estudos Egas Moniz, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.

Departamento de Neurociências e Saúde Mental, ULS de Santa Maria, Centro Académico de Medicina de Lisboa, Lisbon, Portugal.

出版信息

Neurol Sci. 2025 Feb;46(2):929-934. doi: 10.1007/s10072-024-07793-1. Epub 2024 Oct 10.

DOI:10.1007/s10072-024-07793-1
PMID:39387955
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11772508/
Abstract

BACKGROUND

Hereditary transthyretin-mediated amyloidosis (ATTRv amyloidosis) is a rare progressively incapacitating condition with a wide range of genotype/phenotype presentations. It is frequently diagnosed late in its course, particularly in sporadic cases.

OBJECTIVES

Analysing predictors of diagnostic delay in this subpopulation should be, therefore, a priority.

METHODS

109 apparently sporadic ATTRv amyloidosis patients followed in a reference centre in Hospital de Santa Maria (ULS Santa Maria-CAML), in Lisbon, were studied. Time from symptom onset to diagnosis, age, sex, municipality of origin and initial symptoms were obtained. Diagnostic delay was compared between different decades with a Kruskal-Wallis test, and its predictors were evaluated in a univariate model followed by a binary logistic regression analysis to calculate the adjusted odds ratio.

RESULTS

The median diagnostic delay was 1262 days. There was a non-significant difference in diagnostic delay between the 80 s, 90 s, 2000s and 2010s decades. There was a non-significant trend for a longer diagnostic delay in woman and in patients having no neurologic symptoms at onset.

CONCLUSION

There is an important diagnostic delay in sporadic cases of ATTRv amyloidosis. Awareness should be spread among clinicians regarding the various manifestations of this disease, stressing the importance of family history and epidemiological data.

摘要

背景

遗传性转甲状腺素蛋白介导的淀粉样变性病(ATTRv淀粉样变性病)是一种罕见的、逐渐使人丧失能力的疾病,具有广泛的基因型/表型表现。该病常在病程晚期才被诊断出来,尤其是散发病例。

目的

因此,分析该亚群诊断延迟的预测因素应成为首要任务。

方法

对里斯本圣玛丽亚医院(ULS圣玛丽亚 - CAML)参考中心随访的109例明显散发的ATTRv淀粉样变性病患者进行了研究。获取了从症状出现到诊断的时间、年龄、性别、原籍城市和初始症状。采用Kruskal - Wallis检验比较不同年代之间的诊断延迟情况,并在单变量模型中评估其预测因素,随后进行二元逻辑回归分析以计算调整后的优势比。

结果

诊断延迟的中位数为1262天。20世纪80年代、90年代、21世纪初和21世纪10年代之间的诊断延迟没有显著差异。女性和发病时无神经症状的患者诊断延迟较长,但差异不显著。

结论

ATTRv淀粉样变性病散发病例存在重要的诊断延迟。应在临床医生中传播对该疾病各种表现的认识,强调家族史和流行病学数据的重要性。

相似文献

1
Diagnostic delay in patients with sporadic hereditary transthyretin-mediated amyloidosis.散发性遗传性转甲状腺素蛋白介导的淀粉样变性患者的诊断延迟
Neurol Sci. 2025 Feb;46(2):929-934. doi: 10.1007/s10072-024-07793-1. Epub 2024 Oct 10.
2
Hereditary transthyretin amyloidosis in Sweden: Comparisons between a non-endemic and an endemic region.瑞典遗传性转甲状腺素淀粉样变性病:非流行区与流行区的比较。
Amyloid. 2022 Dec;29(4):220-227. doi: 10.1080/13506129.2022.2065191. Epub 2022 Apr 19.
3
The journey to diagnosis of wild-type transthyretin-mediated (ATTRwt) amyloidosis: a path with multisystem involvement.野生型转甲状腺素蛋白介导(ATTRwt)淀粉样变性的诊断之旅:多系统受累的途径。
Orphanet J Rare Dis. 2024 Nov 8;19(1):419. doi: 10.1186/s13023-024-03407-3.
4
Neurological manifestations of hereditary transthyretin amyloidosis: a focus on diagnostic delays.遗传性转甲状腺素蛋白淀粉样变性的神经表现:关注诊断延迟。
Amyloid. 2022 Sep;29(3):184-189. doi: 10.1080/13506129.2022.2046557. Epub 2022 Mar 7.
5
Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy.老年转甲状腺素蛋白心肌病患者遗传性转甲状腺素蛋白淀粉样变性的频率。
Eur J Heart Fail. 2022 Dec;24(12):2367-2373. doi: 10.1002/ejhf.2658. Epub 2022 Sep 11.
6
Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: Recommendations from a panel of experts.美国遗传性转甲状腺素蛋白淀粉样变性伴多发性神经病的诊断与治疗:专家小组建议
Muscle Nerve. 2024 Mar;69(3):273-287. doi: 10.1002/mus.28026. Epub 2024 Jan 4.
7
ATTRv amyloidosis Italian Registry: clinical and epidemiological data.ATTR 淀粉样变意大利登记处:临床和流行病学数据。
Amyloid. 2020 Dec;27(4):259-265. doi: 10.1080/13506129.2020.1794807. Epub 2020 Jul 22.
8
Hereditary transthyretin amyloidosis (ATTRv).遗传性转甲状腺素蛋白淀粉样变性(ATTRv)。
Curr Probl Cardiol. 2025 Apr;50(4):103019. doi: 10.1016/j.cpcardiol.2025.103019. Epub 2025 Feb 13.
9
Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression.监测有症状遗传性转甲状腺素蛋白介导的淀粉样变性病和评估疾病进展的专家意见。
Orphanet J Rare Dis. 2021 Oct 3;16(1):411. doi: 10.1186/s13023-021-01960-9.
10
Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis.遗传性转甲状腺素蛋白淀粉样变性病诊断与管理的新方法。
J Neurol Neurosurg Psychiatry. 2022 Jun;93(6):668-678. doi: 10.1136/jnnp-2021-327909. Epub 2022 Mar 7.

本文引用的文献

1
Hereditary transthyretin amyloid neuropathies: advances in pathophysiology, biomarkers, and treatment.遗传性转甲状腺素蛋白淀粉样变性神经病:病理生理学、生物标志物及治疗方面的进展
Lancet Neurol. 2023 Nov;22(11):1061-1074. doi: 10.1016/S1474-4422(23)00334-4.
2
Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis.ATTRv 淀粉样变治疗和监测的指南和新方向。
Amyloid. 2022 Sep;29(3):143-155. doi: 10.1080/13506129.2022.2052838. Epub 2022 Jun 2.
3
Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis.遗传性转甲状腺素蛋白淀粉样变性病诊断与管理的新方法。
J Neurol Neurosurg Psychiatry. 2022 Jun;93(6):668-678. doi: 10.1136/jnnp-2021-327909. Epub 2022 Mar 7.
4
Hereditary transthyretin amyloidosis overview.遗传性转甲状腺素蛋白淀粉样变性概述。
Neurol Sci. 2022 Dec;43(Suppl 2):595-604. doi: 10.1007/s10072-020-04889-2. Epub 2020 Nov 14.
5
Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy.改善多发性神经病ATTR 淀粉样变症诊断的专家共识建议。
J Neurol. 2021 Jun;268(6):2109-2122. doi: 10.1007/s00415-019-09688-0. Epub 2020 Jan 6.
6
Diagnosis and treatment of urinary and sexual dysfunction in hereditary TTR amyloidosis.遗传性转甲状腺素蛋白淀粉样变性相关泌尿系统和性功能障碍的诊断和治疗。
Clin Auton Res. 2019 Sep;29(Suppl 1):65-74. doi: 10.1007/s10286-019-00627-7. Epub 2019 Aug 26.
7
Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease.遗传性转甲状腺素蛋白淀粉样变性病:致命疾病的医学进步典范。
Nat Rev Neurol. 2019 Jul;15(7):387-404. doi: 10.1038/s41582-019-0210-4. Epub 2019 Jun 17.
8
Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations.通过对 TTR 基因突变的已识别携带者进行有针对性的随访,实现 ATTR 淀粉样变性的早期诊断。
Amyloid. 2019 Mar;26(1):3-9. doi: 10.1080/13506129.2018.1556156. Epub 2019 Feb 22.
9
Epidemiology of Transthyretin Familial Amyloid Polyneuropathy in Portugal: A Nationwide Study.葡萄牙转甲状腺素蛋白家族性淀粉样多发性神经病的流行病学:一项全国性研究。
Neuroepidemiology. 2018;51(3-4):177-182. doi: 10.1159/000490553. Epub 2018 Aug 28.
10
A new staging system for cardiac transthyretin amyloidosis.心脏转甲状腺素蛋白淀粉样变性的新分期系统。
Eur Heart J. 2018 Aug 7;39(30):2799-2806. doi: 10.1093/eurheartj/ehx589.